KalVista Pharmaceuticals (KALV) Receivables Refunds (2017 - 2024)
Historic Receivables Refunds for KalVista Pharmaceuticals (KALV) over the last 7 years, with Q4 2024 value amounting to $11.4 million.
- KalVista Pharmaceuticals' Receivables Refunds changed N/A to $11.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was $11.4 million, marking a year-over-year change of. This contributed to the annual value of $8.4 million for FY2024, which is N/A changed from last year.
- Per KalVista Pharmaceuticals' latest filing, its Receivables Refunds stood at $11.4 million for Q4 2024.
- In the past 5 years, KalVista Pharmaceuticals' Receivables Refunds ranged from a high of $23.0 million in Q1 2024 and a low of $7.6 million during Q1 2021
- Moreover, its 4-year median value for Receivables Refunds was $13.7 million (2020), whereas its average is $14.1 million.
- Its Receivables Refunds has fluctuated over the past 5 years, first surged by 6502.79% in 2020, then tumbled by 4873.34% in 2021.
- Quarter analysis of 4 years shows KalVista Pharmaceuticals' Receivables Refunds stood at $14.7 million in 2020, then tumbled by 48.32% to $7.6 million in 2021, then surged by 163.22% to $20.0 million in 2023, then tumbled by 42.85% to $11.4 million in 2024.
- Its last three reported values are $11.4 million in Q4 2024, $11.1 million for Q4 2024, and $9.9 million during Q3 2024.